Axa S.A. Has $16.12 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Axa S.A. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 76,236 shares of the medical research company’s stock after buying an additional 7,393 shares during the period. Axa S.A.’s holdings in IQVIA were worth $16,119,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares in the last quarter. Morningstar Investment Services LLC increased its position in shares of IQVIA by 96.9% during the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after acquiring an additional 606,333 shares in the last quarter. Capital Research Global Investors increased its position in shares of IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after acquiring an additional 592,372 shares in the last quarter. 1832 Asset Management L.P. increased its position in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of IQVIA during the second quarter worth $70,610,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $234.56 on Friday. The company has a market capitalization of $42.74 billion, a price-to-earnings ratio of 32.04, a PEG ratio of 2.26 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a 50-day simple moving average of $241.29 and a 200 day simple moving average of $233.69.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.22 earnings per share. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Analysts Set New Price Targets

IQV has been the subject of several research reports. UBS Group increased their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Robert W. Baird raised their target price on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Evercore ISI boosted their price target on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, JPMorgan Chase & Co. upped their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.00.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.